|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
3
|
Sue-Ling HM, Johnston D, Martin IG, et al:
Gastric cancer: a curable disease in Britain. BMJ. 307:591–596.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Menges M and Hoehler T: Current strategies
in systemic treatment of gastric cancer and cancer of the
gastroesophageal junction. J Cancer Res Clin Oncol. 135:29–38.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ajani JA: Evolving chemotherapy for
advanced gastric cancer. Oncologist. 10(Suppl 3): 49–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slamon DJ, Leyland-Jones B, Shak S, et al:
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yokota J, Yamamoto T, Miyajima N, et al:
Genetic alterations of the c-erbB-2 oncogene occur frequently in
tubular adenocarcinoma of the stomach and are often accompanied by
amplification of the v-erbA homologue. Oncogene. 2:283–287.
1988.PubMed/NCBI
|
|
10
|
Hofmann M, Stoss O, Shi D, et al:
Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology. 52:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanner M, Hollmen M, Junttila TT, et al:
Amplification of HER-2 in gastric carcinoma: association with
Topoisomerase IIα gene amplification, intestinal type, poor
prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278.
2005.PubMed/NCBI
|
|
12
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hattori Y, Itoh H, Uchino S, et al:
Immunohistochemical detection of K-sam protein in stomach cancer.
Clin Cancer Res. 2:1373–1381. 1996.PubMed/NCBI
|
|
14
|
Ueda T, Sasaki H, Kuwahara Y, et al:
Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short
homology-mediated recombination, generating preferential expression
of specific messenger RNAs. Cancer Res. 59:6080–6086. 1999.
|
|
15
|
Tsujimoto H, Sugihara H, Hagiwara A and
Hattori T: Amplification of growth factor receptor genes and DNA
ploidy pattern in the progression of gastric cancer. Virchows Arch.
431:383–389. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar
|
|
17
|
Neve RM, Lane HA and Hynes NE: The role of
overexpressed HER2 in transformation. Ann Oncol. 12(Suppl 1): 9–13.
2001. View Article : Google Scholar
|
|
18
|
Yokoyama H, Ikehara Y, Kodera Y, et al:
Molecular basis for sensitivity and acquired resistance to
gefitinib in HER2-overexpressing human gastric cancer cell lines
derived from liver metastasis. Br J Cancer. 95:1504–1513. 2006.
View Article : Google Scholar
|
|
19
|
Matsui Y, Inomata M, Tojigamori M, Sonoda
K, Shiraishi N and Kitano S: Suppression of tumor growth in human
gastric cancer with HER2 overexpression by an anti-HER2 antibody in
a murine model. Int J Oncol. 27:681–685. 2005.PubMed/NCBI
|
|
20
|
Lane HA, Beuvink I, Motoyama AB, Daly JM,
Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation
through modulation of p27(Kip1)-Cdk2 complex formation: receptor
overexpression does not determine growth dependency. Mol Cell Biol.
20:3210–3223. 2000. View Article : Google Scholar
|
|
21
|
Abramoff MD, Magalhaes PJ and Ram SJ:
Image processing with ImageJ. Biophotonics Int. 11:36–42. 2004.
|
|
22
|
Pegram MD, Konecny GE, O’Callaghan C,
Beryt M, Pietras R and Slamon DJ: Rational combinations of
trastuzumab with chemotherapeutic drugs used in the treatment of
breast cancer. J Natl Cancer Inst. 96:739–749. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gong SJ, Jin CJ, Rha SY and Chung HC:
Growth inhibitory effects of trastuzumab and chemotherapeutic drugs
in gastric cancer cell lines. Cancer Lett. 214:215–224. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yokozaki H: Molecular characteristics of
eight gastric cancer cell lines established in Japan. Pathol Int.
50:767–777. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mita H, Toyota M, Aoki F, et al: A novel
method, digital genome scanning detects KRAS gene amplification in
gastric cancers: involvement of overexpressed wild-type KRAS in
downstream signaling and cancer cell growth. BMC Cancer. 9:1982009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sharma P and Halayko AJ: Emerging
molecular targets for the treatment of asthma. Indian J Biochem
Biophys. 46:447–460. 2009.PubMed/NCBI
|
|
28
|
Kim SY, Kim HP, Kim YJ, et al: Trastuzumab
inhibits the growth of human gastric cancer cell lines with HER2
amplification synergistically with cisplatin. Int J Oncol.
32:89–95. 2008.PubMed/NCBI
|
|
29
|
Tanizaki J, Okamoto I, Takezawa K, et al:
Synergistic antitumor effect of S-1 and HER2-targeting agents in
gastric cancer with HER2 amplification. Mol Cancer Ther.
9:1198–1207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kataoka Y, Mukohara T, Shimada H, Saijo N,
Hirai M and Minami H: Association between gain-of-function
mutations in PIK3CA and resistance to HER2-targeted agents in
HER2-amplified breast cancer cell lines. Ann Oncol. 21:255–262.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harada H, Andersen JS, Mann M, Terada N
and Korsmeyer SJ: p70S6 kinase signals cell survival as well as
growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad
Sci USA. 98:9666–9670. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Doi T, Muro K, Boku N, et al: Multicenter
phase II study of everolimus in patients with previously treated
metastatic gastric cancer. J Clin Oncol. 28:1904–1910. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Danilkovitch-Miagkova A and Zbar B:
Dysregulation of Met receptor tyrosine kinase activity in invasive
tumors. J Clin Invest. 109:863–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lim T, Lee J, Lee DJ, et al: Phase I trial
of capecitabine plus everolimus (RAD001) in patients with
previously treated metastatic gastric cancer. Cancer Chemother
Pharmacol. 68:255–262. 2011. View Article : Google Scholar : PubMed/NCBI
|
